cas 19064-64-3|| where to buy 3,6-dichloro-4-methylpyridazine

Nom du produit:3,6-dichloro-4-methylpyridazine

IUPAC Name:3,6-dichloro-4-methylpyridazine

Unité d'emballage	Stock disponible	Prix($)
CM102253-100g	in stock	ǤĲ
CM102253-500g	in stock	ŗŹǤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 19064-64-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:19064-64-3; Formule moléculaire:C5H4Cl2N2; Point de fusion:-; Code SMILES:CC1=CC(Cl)=NN=C1Cl; Densité:

: Numéro de catalogue:CM102253; Poids moléculaire:163; Point d'ébullition:272.1°C; N° Mdl:MFCD00006465; Stockage:Store at 2-8°C.

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.